Featured in Morgans' 'Under The Microscope' Podcast series
Regeneus CEO Leo Lee spoke with Ian Wilkie, an Analyst at Morgans, about the company's platform technologies Progenza and Sygenus, why there is an unmet need in pain and inflammation treatment and how the company's novel stem cell technology address this market.
In the interview, Leo also highlighted the company's upcoming milestones and why he believes stem cell technologies have the potential to be the next plaform to address major diseases and chronic illnesses.
To listen to the full interview, please visit:
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.